The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe








